Free Trial
NASDAQ:ENSC

Ensysce Biosciences (ENSC) Stock Price, News & Analysis

Ensysce Biosciences logo
$2.05 -0.04 (-1.91%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.04 0.00 (-0.24%)
As of 08/1/2025 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Ensysce Biosciences Stock (NASDAQ:ENSC)

Key Stats

Today's Range
$1.98
$2.18
50-Day Range
$2.02
$2.38
52-Week Range
$1.62
$14.67
Volume
435,767 shs
Average Volume
843,251 shs
Market Capitalization
$4.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Ensysce Biosciences Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
10th Percentile Overall Score

ENSC MarketRank™: 

Ensysce Biosciences scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Ensysce Biosciences.

  • Earnings Growth

    Earnings for Ensysce Biosciences are expected to decrease in the coming year, from ($8.33) to ($12.77) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Ensysce Biosciences is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Ensysce Biosciences is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Ensysce Biosciences has a P/B Ratio of 0.79. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Ensysce Biosciences' valuation and earnings.
  • Percentage of Shares Shorted

    6.72% of the outstanding shares of Ensysce Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Ensysce Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ensysce Biosciences has recently decreased by 41.57%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Ensysce Biosciences does not currently pay a dividend.

  • Dividend Growth

    Ensysce Biosciences does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    6.72% of the outstanding shares of Ensysce Biosciences have been sold short.
  • Short Interest Ratio / Days to Cover

    Ensysce Biosciences has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Ensysce Biosciences has recently decreased by 41.57%, indicating that investor sentiment is improving significantly.
  • Search Interest

    2 people have searched for ENSC on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    1 people have added Ensysce Biosciences to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Ensysce Biosciences insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.90% of the stock of Ensysce Biosciences is held by insiders.

  • Percentage Held by Institutions

    Only 5.63% of the stock of Ensysce Biosciences is held by institutions.

  • Read more about Ensysce Biosciences' insider trading history.
Receive ENSC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ensysce Biosciences and its competitors with MarketBeat's FREE daily newsletter.

ENSC Stock News Headlines

He Called Nvidia at $1.10. Now, He Says THIS Stock Will…
The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvidia at $1.10 reveals AI’s Next Magnificent Seven… including one stock he says could become America’s next trillion-dollar giant.
Ensysce Flat on Receiving Grant
Ensysce Biosciences secures patent for OUD treatment
See More Headlines

ENSC Stock Analysis - Frequently Asked Questions

Ensysce Biosciences' stock was trading at $8.14 on January 1st, 2025. Since then, ENSC shares have decreased by 74.8% and is now trading at $2.05.

Ensysce Biosciences, Inc. (NASDAQ:ENSC) released its quarterly earnings results on Tuesday, May, 13th. The company reported ($1.39) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($3.02) by $1.63. The firm earned $1.32 million during the quarter, compared to analysts' expectations of $0.65 million. Ensysce Biosciences had a negative trailing twelve-month return on equity of 192.54% and a negative net margin of 109.49%.

Shares of Ensysce Biosciences reverse split before market open on Friday, March 31st 2023.The 1-12 reverse split was announced on Friday, March 31st 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, March 31st 2023. An investor that had 100 shares of stock prior to the reverse split would have 8 shares after the split.

Shares of ENSC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Ensysce Biosciences investors own include Predictive Oncology (POAI), NVIDIA (NVDA), JPMorgan Chase & Co. (JPM), Abbott Laboratories (ABT), Meta Platforms (META), Insulet (PODD) and Broadcom (AVGO).

Company Calendar

Last Earnings
5/13/2025
Today
8/02/2025
Next Earnings (Estimated)
8/13/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ENSC
CIK
1716947
Fax
N/A
Employees
10
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($6.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$7.99 million
Net Margins
-109.49%
Pretax Margin
-109.49%
Return on Equity
-192.54%
Return on Assets
-121.77%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.50
Quick Ratio
2.50

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$2.59 per share
Price / Book
0.79

Miscellaneous

Outstanding Shares
2,371,000
Free Float
2,184,000
Market Cap
$4.86 million
Optionable
Not Optionable
Beta
0.98
Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ENSC) was last updated on 8/2/2025 by MarketBeat.com Staff
From Our Partners